NYSE:AVNS

Avanos Medical Competitors

$45.03
+0.15 (+0.33 %)
(As of 04/23/2021 12:48 PM ET)
Add
Compare
Today's Range
$44.87
Now: $45.03
$45.34
50-Day Range
$42.69
MA: $45.29
$48.23
52-Week Range
$24.71
Now: $45.03
$53.61
Volume3,315 shs
Average Volume244,463 shs
Market Capitalization$2.16 billion
P/E Ratio155.28
Dividend YieldN/A
Beta1.12

Competitors

Avanos Medical (NYSE:AVNS) Vs. MSA, EAR, ESTA, INGN, SIEN, and IVC

Should you be buying AVNS stock or one of its competitors? Companies in the industry of "surgical appliances & supplies" are considered alternatives and competitors to Avanos Medical, including MSA Safety (MSA), Eargo (EAR), Establishment Labs (ESTA), Inogen (INGN), Sientra (SIEN), and Invacare (IVC).

Avanos Medical (NYSE:AVNS) and MSA Safety (NYSE:MSA) are both mid-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, earnings, profitability, valuation, risk, analyst recommendations and institutional ownership.

Earnings & Valuation

This table compares Avanos Medical and MSA Safety's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Avanos Medical$697.60 million3.11$-45,900,000.00$1.0742.17
MSA Safety$1.40 billion4.47$136.44 million$4.8033.40

MSA Safety has higher revenue and earnings than Avanos Medical. MSA Safety is trading at a lower price-to-earnings ratio than Avanos Medical, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Avanos Medical and MSA Safety's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Avanos Medical1.93%3.20%2.28%
MSA Safety10.40%23.96%10.13%

Institutional & Insider Ownership

94.8% of Avanos Medical shares are owned by institutional investors. Comparatively, 77.2% of MSA Safety shares are owned by institutional investors. 1.5% of Avanos Medical shares are owned by company insiders. Comparatively, 7.0% of MSA Safety shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Analyst Ratings

This is a summary of recent ratings and recommmendations for Avanos Medical and MSA Safety, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Avanos Medical10102.00
MSA Safety01202.67

Avanos Medical currently has a consensus price target of $50.00, indicating a potential upside of 11.11%. MSA Safety has a consensus price target of $151.50, indicating a potential downside of 6.01%. Given Avanos Medical's higher possible upside, research analysts plainly believe Avanos Medical is more favorable than MSA Safety.

Risk and Volatility

Avanos Medical has a beta of 1.12, meaning that its share price is 12% more volatile than the S&P 500. Comparatively, MSA Safety has a beta of 0.96, meaning that its share price is 4% less volatile than the S&P 500.

Summary

MSA Safety beats Avanos Medical on 10 of the 14 factors compared between the two stocks.

Avanos Medical (NYSE:AVNS) and Eargo (NASDAQ:EAR) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, earnings, profitability, valuation, risk, analyst recommendations and institutional ownership.

Profitability

This table compares Avanos Medical and Eargo's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Avanos Medical1.93%3.20%2.28%
EargoN/AN/AN/A

Analyst Ratings

This is a summary of recent ratings and recommmendations for Avanos Medical and Eargo, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Avanos Medical10102.00
Eargo00403.00

Avanos Medical currently has a consensus price target of $50.00, indicating a potential upside of 11.11%. Eargo has a consensus price target of $48.00, indicating a potential downside of 2.58%. Given Avanos Medical's higher possible upside, research analysts plainly believe Avanos Medical is more favorable than Eargo.

Earnings & Valuation

This table compares Avanos Medical and Eargo's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Avanos Medical$697.60 million3.11$-45,900,000.00$1.0742.17
EargoN/AN/AN/AN/AN/A

Eargo has lower revenue, but higher earnings than Avanos Medical.

Institutional & Insider Ownership

94.8% of Avanos Medical shares are owned by institutional investors. 1.5% of Avanos Medical shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

Avanos Medical beats Eargo on 7 of the 9 factors compared between the two stocks.

Establishment Labs (NASDAQ:ESTA) and Avanos Medical (NYSE:AVNS) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, profitability, valuation, risk, institutional ownership, earnings and analyst recommendations.

Profitability

This table compares Establishment Labs and Avanos Medical's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Establishment Labs-46.40%-49.51%-24.21%
Avanos Medical1.93%3.20%2.28%

Analyst Recommendations

This is a breakdown of recent ratings for Establishment Labs and Avanos Medical, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Establishment Labs01302.75
Avanos Medical10102.00

Establishment Labs currently has a consensus target price of $46.00, indicating a potential downside of 36.54%. Avanos Medical has a consensus target price of $50.00, indicating a potential upside of 11.11%. Given Avanos Medical's higher probable upside, analysts plainly believe Avanos Medical is more favorable than Establishment Labs.

Earnings and Valuation

This table compares Establishment Labs and Avanos Medical's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Establishment Labs$89.57 million19.17$-38,150,000.00($1.86)-38.97
Avanos Medical$697.60 million3.11$-45,900,000.00$1.0742.17

Establishment Labs has higher earnings, but lower revenue than Avanos Medical. Establishment Labs is trading at a lower price-to-earnings ratio than Avanos Medical, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

54.8% of Establishment Labs shares are held by institutional investors. Comparatively, 94.8% of Avanos Medical shares are held by institutional investors. 2.6% of Establishment Labs shares are held by insiders. Comparatively, 1.5% of Avanos Medical shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Volatility & Risk

Establishment Labs has a beta of 1.15, indicating that its stock price is 15% more volatile than the S&P 500. Comparatively, Avanos Medical has a beta of 1.12, indicating that its stock price is 12% more volatile than the S&P 500.

Summary

Avanos Medical beats Establishment Labs on 8 of the 14 factors compared between the two stocks.

Inogen (NASDAQ:INGN) and Avanos Medical (NYSE:AVNS) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, profitability, valuation, risk, institutional ownership, earnings and analyst recommendations.

Profitability

This table compares Inogen and Avanos Medical's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Inogen-0.66%0.21%0.16%
Avanos Medical1.93%3.20%2.28%

Analyst Recommendations

This is a breakdown of recent ratings for Inogen and Avanos Medical, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Inogen03102.25
Avanos Medical10102.00

Inogen currently has a consensus target price of $63.00, indicating a potential downside of 2.75%. Avanos Medical has a consensus target price of $50.00, indicating a potential upside of 11.11%. Given Avanos Medical's higher probable upside, analysts plainly believe Avanos Medical is more favorable than Inogen.

Earnings and Valuation

This table compares Inogen and Avanos Medical's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Inogen$361.94 million3.98$20.95 million$1.0760.32
Avanos Medical$697.60 million3.11$-45,900,000.00$1.0742.17

Inogen has higher earnings, but lower revenue than Avanos Medical. Avanos Medical is trading at a lower price-to-earnings ratio than Inogen, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

95.1% of Inogen shares are held by institutional investors. Comparatively, 94.8% of Avanos Medical shares are held by institutional investors. 4.8% of Inogen shares are held by insiders. Comparatively, 1.5% of Avanos Medical shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Volatility & Risk

Inogen has a beta of 1.05, indicating that its stock price is 5% more volatile than the S&P 500. Comparatively, Avanos Medical has a beta of 1.12, indicating that its stock price is 12% more volatile than the S&P 500.

Summary

Avanos Medical beats Inogen on 7 of the 12 factors compared between the two stocks.

Sientra (NASDAQ:SIEN) and Avanos Medical (NYSE:AVNS) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, profitability, valuation, risk, institutional ownership, earnings and analyst recommendations.

Profitability

This table compares Sientra and Avanos Medical's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Sientra-123.88%-174.05%-38.97%
Avanos Medical1.93%3.20%2.28%

Analyst Recommendations

This is a breakdown of recent ratings for Sientra and Avanos Medical, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Sientra00403.00
Avanos Medical10102.00

Sientra currently has a consensus target price of $10.00, indicating a potential upside of 47.28%. Avanos Medical has a consensus target price of $50.00, indicating a potential upside of 11.11%. Given Sientra's stronger consensus rating and higher probable upside, equities analysts plainly believe Sientra is more favorable than Avanos Medical.

Earnings and Valuation

This table compares Sientra and Avanos Medical's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Sientra$83.70 million4.68$-106,820,000.00($2.29)-2.99
Avanos Medical$697.60 million3.11$-45,900,000.00$1.0742.17

Avanos Medical has higher revenue and earnings than Sientra. Sientra is trading at a lower price-to-earnings ratio than Avanos Medical, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

71.0% of Sientra shares are held by institutional investors. Comparatively, 94.8% of Avanos Medical shares are held by institutional investors. 2.8% of Sientra shares are held by insiders. Comparatively, 1.5% of Avanos Medical shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Volatility & Risk

Sientra has a beta of 1.81, indicating that its stock price is 81% more volatile than the S&P 500. Comparatively, Avanos Medical has a beta of 1.12, indicating that its stock price is 12% more volatile than the S&P 500.

Summary

Avanos Medical beats Sientra on 8 of the 14 factors compared between the two stocks.

Invacare (NYSE:IVC) and Avanos Medical (NYSE:AVNS) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, profitability, valuation, risk, institutional ownership, earnings and analyst recommendations.

Insider and Institutional Ownership

96.7% of Invacare shares are held by institutional investors. Comparatively, 94.8% of Avanos Medical shares are held by institutional investors. 3.2% of Invacare shares are held by insiders. Comparatively, 1.5% of Avanos Medical shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Profitability

This table compares Invacare and Avanos Medical's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Invacare-4.87%-8.76%-3.07%
Avanos Medical1.93%3.20%2.28%

Earnings and Valuation

This table compares Invacare and Avanos Medical's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Invacare$927.96 million0.33$-53,330,000.00($1.06)-8.40
Avanos Medical$697.60 million3.11$-45,900,000.00$1.0742.17

Avanos Medical has lower revenue, but higher earnings than Invacare. Invacare is trading at a lower price-to-earnings ratio than Avanos Medical, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of recent ratings for Invacare and Avanos Medical, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Invacare00103.00
Avanos Medical10102.00

Invacare currently has a consensus target price of $17.00, indicating a potential upside of 92.09%. Avanos Medical has a consensus target price of $50.00, indicating a potential upside of 11.11%. Given Invacare's stronger consensus rating and higher probable upside, equities analysts plainly believe Invacare is more favorable than Avanos Medical.

Volatility & Risk

Invacare has a beta of 0.94, indicating that its stock price is 6% less volatile than the S&P 500. Comparatively, Avanos Medical has a beta of 1.12, indicating that its stock price is 12% more volatile than the S&P 500.

Summary

Avanos Medical beats Invacare on 8 of the 13 factors compared between the two stocks.


Avanos Medical Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
MSA Safety logo
MSA
MSA Safety
2.1$160.31+1.0%$6.20 billion$1.40 billion45.41Upcoming Earnings
Eargo logo
EAR
Eargo
1.0$49.24+0.4%$1.88 billionN/A0.00Insider Selling
News Coverage
Establishment Labs logo
ESTA
Establishment Labs
1.2$72.49+0.8%$1.70 billion$89.57 million-42.89
Inogen logo
INGN
Inogen
1.2$64.54+0.1%$1.44 billion$361.94 million-717.03
Sientra logo
SIEN
Sientra
1.6$6.84+3.2%$379.15 million$83.70 million-3.84Analyst Upgrade
Invacare logo
IVC
Invacare
1.6$8.90+1.9%$300.52 million$927.96 million-7.24News Coverage
Lakeland Industries logo
LAKE
Lakeland Industries
1.8$28.73+0.0%$230.62 million$107.81 million8.16Analyst Report
News Coverage
SMTI
Sanara MedTech
0.8$27.75+1.7%$207.72 million$11.77 million-21.51
Surgalign logo
SRGA
Surgalign
1.7$1.92+3.6%$204.00 million$308.38 million-1.07
Surgalign logo
SRGA
Surgalign
1.4$1.92+3.6%$204.00 million$308.38 million-1.07
Conformis logo
CFMS
Conformis
1.3$0.93+7.5%$156.89 million$77.43 million-2.74Analyst Downgrade
News Coverage
Gap Down
ReWalk Robotics logo
RWLK
ReWalk Robotics
1.4$1.87+0.5%$85.76 million$4.87 million-1.48Gap Down
CollPlant Biotechnologies logo
CLGN
CollPlant Biotechnologies
1.1$14.50+0.1%$82.19 million$2.32 million-7.25
Predictive Oncology logo
POAI
Predictive Oncology
1.3$1.03+4.9%$52.70 million$1.41 million-0.16
AHPI
Allied Healthcare Products
0.5$4.69+0.2%$18.77 million$31.89 million0.00
NanoVibronix logo
NAOV
NanoVibronix
0.5$0.91+1.8%$12.40 million$530,000.00-1.51Gap Down
This page was last updated on 4/23/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.